Your browser is no longer supported. Please, upgrade your browser.
Settings
ESPR Esperion Therapeutics, Inc. daily Stock Chart
ESPR [NASD]
Esperion Therapeutics, Inc.
Index- P/E- EPS (ttm)-5.77 Insider Own2.77% Shs Outstand25.07M Perf Week-3.42%
Market Cap1.25B Forward P/E- EPS next Y-5.59 Insider Trans-54.66% Shs Float22.71M Perf Month13.30%
Income-130.20M PEG- EPS next Q-1.79 Inst Own98.10% Short Float21.50% Perf Quarter21.09%
Sales- P/S- EPS this Y-47.10% Inst Trans14.59% Short Ratio6.41 Perf Half Y27.33%
Book/sh6.82 P/B7.28 EPS next Y23.30% ROA-57.30% Target Price60.85 Perf Year267.65%
Cash/sh6.68 P/C7.44 EPS next 5Y5.76% ROE-62.80% 52W Range9.40 - 57.38 Perf YTD296.73%
Dividend- P/FCF- EPS past 5Y38.00% ROI- 52W High-13.44% Beta2.68
Dividend %- Quick Ratio5.50 Sales past 5Y- Gross Margin- 52W Low428.40% ATR2.05
Employees44 Current Ratio5.50 Sales Q/Q- Oper. Margin- RSI (14)50.75 Volatility3.64% 4.23%
OptionableYes Debt/Eq0.01 EPS Q/Q-208.10% Profit Margin- Rel Volume0.50 Prev Close49.57
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout- Avg Volume761.68K Price49.67
Recom2.10 SMA200.80% SMA503.22% SMA20049.96% Volume379,865 Change0.20%
Aug-29-17Initiated Northland Capital Outperform $72
Aug-11-17Resumed BofA/Merrill Neutral
Aug-09-17Upgrade Jefferies Hold → Buy
Jul-11-17Initiated Jefferies Hold
Jun-27-17Reiterated Stifel Buy $45 → $60
Jun-23-17Initiated Deutsche Bank Buy $48
Mar-30-17Upgrade UBS Neutral → Buy $23 → $52
Mar-20-17Upgrade Credit Suisse Underperform → Neutral
Feb-28-17Upgrade Citigroup Neutral → Buy
Feb-23-17Reiterated RBC Capital Mkts Sector Perform $20 → $30
Nov-14-16Downgrade Citigroup Buy → Neutral
Jul-05-16Downgrade WallachBeth Buy → Hold $35
Jun-30-16Reiterated Needham Buy $77 → $25
Jun-29-16Downgrade RBC Capital Mkts Outperform → Sector Perform $30 → $15
Jun-29-16Downgrade JP Morgan Overweight → Neutral
Jun-29-16Downgrade Credit Suisse Neutral → Underperform
Feb-26-16Reiterated Chardan Capital Markets Neutral $18 → $13
Feb-25-16Reiterated Stifel Buy $105 → $64
Dec-15-15Reiterated RBC Capital Mkts Outperform $65 → $40
Nov-06-15Reiterated RBC Capital Mkts Outperform $105 → $65
Aug-28-17 07:12PM  Cramer Remix: Here's how North Korea's missile could impa... CNBC Videos
06:59PM  Cramer Remix: Here's how North Korea's missile could impact the stock market CNBC
Aug-18-17 07:17AM  These Stocks Have Quadrupled Since Last Year Motley Fool
Aug-14-17 04:30PM  Edited Transcript of ESPR earnings conference call or presentation 8-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
11:49AM  The Zacks Analyst Blog Highlights: Mylan, Perrigo, Esperion's, Zynerba and Valeant Zacks
Aug-11-17 04:30PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
07:05AM  Pharma Stock Roundup: Mylan Misses, Perrigo Tops in Q2, Zynerba Plunges on Study Failure Zacks
Aug-09-17 09:20PM  Esperion Prices Public Offering of Common Stock GlobeNewswire
08:10AM  Today's Research Reports on Stocks to Watch: Esperion Therapeutics and Valeant Pharmaceuticals ACCESSWIRE
Aug-08-17 11:56PM  Esperion Therapeutics reports 2Q loss Associated Press +15.41%
04:32PM  Esperion Announces Proposed Public Offering of Common Stock GlobeNewswire
12:46PM  Here's What's Pushing Up Esperion Therapeutics Inc. Today Motley Fool
08:00AM  Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results GlobeNewswire
07:30AM  Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin GlobeNewswire
05:20AM  Investor Network: Esperion Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-17 08:59AM  Should You Buy Esperion Therapeutics (ESPR) Ahead of Earnings? Zacks
Aug-02-17 04:30PM  Esperion to Provide Bempedoic Acid Franchise Development Program Updates and Second Quarter Financial Results GlobeNewswire
Aug-01-17 06:29PM  What to Expect from Epizyme (EPZM) This Earnings Season? Zacks
11:56AM  What's in the Cards for Endo (ENDP) this Earnings Season? Zacks
Jul-26-17 04:30PM  Esperion Announces Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor GlobeNewswire
03:59PM  The CEO Behind Lipitor Is Working on a Promising New Cholesterol Drug Motley Fool
Jul-21-17 02:42PM  3 Been-There-Done-That Biotech CEOs Who Are Doing it Again Motley Fool
Jul-20-17 09:02PM  3 Hottest Biotech Stocks of 2017 -- Are They Still Buys Now? Motley Fool +5.63%
Jul-17-17 07:00AM  3 Small Biotech Stocks Being Run by Proven Winners Motley Fool
Jun-30-17 05:46PM  3 Stocks That Turned $7,000 Into As Much As $37,000 So Far in 2017 Motley Fool
Jun-29-17 08:20AM  Esperion Therapeutics (ESPR) Looks Good: Stock Gains 10.4% Zacks
08:00AM  Today's Research Reports on Stocks to Watch: Heat Biologics Inc. and Esperion Therapeutics Accesswire
Jun-28-17 06:14PM  Here's Why Shares of Esperion Therapeutics (ESPR) Popped Today Zacks +10.38%
04:17PM  Esperion Breaks Out On Cholesterol Tie-Up With Dow's Merck Investor's Business Daily
10:30AM  Esperion's Combo Cholesterol Candidate Enters Phase III Zacks
Jun-26-17 04:05PM  Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe GlobeNewswire
Jun-23-17 09:54AM  Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold Benzinga
Jun-22-17 03:42PM  If Esperion Wants to Market the Next Big Cholesterol Drug, It Will Take Strategy Motley Fool
12:19PM  3 Hot Plays in the Resurgent Biotech Sector Investopedia
Jun-21-17 04:33PM  Biotechs Surge As Generalists Return Amid Subsiding Trump Woes Investor's Business Daily +19.21%
Jun-14-17 04:30PM  Esperion to Present at the JMP Securities 2017 Life Sciences Conference GlobeNewswire
Jun-09-17 01:19PM  Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct TheStreet.com
May-31-17 04:30PM  Esperion to Present at the Jefferies 2017 Global Healthcare Conference GlobeNewswire
May-22-17 08:05AM  Esperion Provides Update on Common Stock Trading Activity GlobeNewswire
May-19-17 04:30PM  Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference GlobeNewswire -8.14%
May-18-17 04:30PM  Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
May-12-17 04:30PM  Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2017 Healthcare Conference GlobeNewswire
May-08-17 08:00AM  Today's Research Report on Biotech Stocks to Watch: Immunomedics and Esperion Therapeutics Accesswire
May-06-17 08:01AM  Why Esperion Therapeutics Shares Were Flat In April Motley Fool
May-05-17 05:02AM  Esperion Therapeutics reports 1Q loss Associated Press -5.22%
May-04-17 04:05PM  Esperion Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2017 Financial Results GlobeNewswire
May-01-17 02:32PM  3 Best Biotech Stocks During Trump's First 100 Days Motley Fool
Apr-28-17 09:21AM  Biotech And Pharma Industry And Stock News Investor's Business Daily
Apr-26-17 05:28PM  Amgen Trips Amid Rivals: Sales Miss By $100 Million, But Earnings Top Investor's Business Daily
Apr-11-17 07:02AM  3 Clinical-Stage Biotech Stocks That Could Be About to Strike It Rich Motley Fool
Apr-10-17 06:51PM  Cramer's lightning round: I may be alone on this, but this e-commerce play is going higher CNBC +7.57%
Apr-07-17 09:30AM  The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics Zacks
Apr-06-17 09:32AM  3 of the Best & Worst Performing Drug Stocks of Q1 Zacks
Mar-31-17 08:21AM  Could Pfizer Buy Esperion Therapeutics? Motley Fool
Mar-30-17 04:20PM  The 3 Best Cholesterol Drug Stocks to Buy in 2017 Motley Fool
04:08PM  Which Biotechs Are Buyable As Sector Recovers In 2017? Investor's Business Daily
10:33AM  5 Top Performing Stocks of the Best ETF of Q1 Zacks
09:03AM  Esperion Therapeutics upgraded by UBS
Mar-28-17 04:30PM  Esperion to Participate in Fireside Chat at the 16th Annual Needham Healthcare Conference GlobeNewswire -6.82%
Mar-24-17 12:00PM  3 Hot Biotech Stocks Now Motley Fool
Mar-21-17 10:10AM  Company News for March 21, 2017 Zacks -5.26%
09:32AM  Biotech Premarket Movers: Esperion, Minerva and BioCryst
09:30AM  The Difference Between Spectacular News and No News Accesswire
Mar-20-17 08:08PM  Esperion Therapeutics Inc (ESPR): Get It While Its Cheap Insider Monkey +74.14%
06:21PM  After-hours buzz: ESPR, NKTR, MMSI & more at CNBC
05:02PM  Here's What Pushed Esperion Therapeutics Inc Stock Higher Today at Motley Fool
04:09PM  Esperion And Medicines Co. Recover From Amgen-Induced Pitfall
02:03PM  How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More
12:42PM  Nektar, AMD, Esperion, and More: Heres Why These Five Stocks Are Surging at Insider Monkey
12:05PM  Esperion Gets FDA Nod for Cholesterol Drug Program at Investopedia
11:01AM  Esperion Therapeutics stock surges 52% after it says the FDA gave its drug program positive feedback at MarketWatch
10:55AM  Mondays Top Biopharma Movers
09:35AM  Biotech Premarket Movers: CytomX, Aevi, Esperion
07:46AM  ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:32AM  Esperion Therapeutics Sees Clear FDA Path For Its Heart Drug at Forbes
07:30AM  Esperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic Acid GlobeNewswire
Mar-17-17 04:50PM  Esperion's Dive On Amgen Heart Study 'Counterintuitive' On Pricing -20.17%
04:28PM  Amgen Tanks On Heart Study; Shares Of Other Drugmakers Tumble
02:56PM  Amgen, Esperion, AmTrust Financial and More: What is Going On With These Falling Stocks? at Insider Monkey
01:18PM  Here's Why Amgen, The Medicines Company, and Esperion Therapeutics Are All Tanking Today at Motley Fool
11:03AM  [video]AveXis, Esperion and Amgen Among Biotech Movers
Mar-14-17 04:06PM  Amgen Could Boost Rivals On Positive Heart-Disease Study: Analyst
Mar-09-17 08:15AM  Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 8.6%
Mar-08-17 04:26PM  Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High +8.59%
Mar-07-17 08:47AM  ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  Esperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/Atorvastatin GlobeNewswire
Mar-06-17 08:30AM  Esperion Announces Oral Presentation on Genetic Validation of ATP Citrate Lyase Inhibition at the American College of Cardiology 66th Annual Scientific Session GlobeNewswire
Mar-02-17 03:34PM  Biotechs Breaking Out On Drug Development News at Forbes
Mar-01-17 04:21PM  Here's Why Esperion Therapeutics Inc Stock Popped Today at Motley Fool +16.32%
Feb-28-17 01:04PM  ESPERION THERAPEUTICS, INC. Financials
Feb-27-17 07:39PM  Cramer's lightning round: The only Chinese stock I will recommend at CNBC +6.50%
Feb-24-17 05:42PM  3 Biotech Long Shots: Boom Or Bust? at Motley Fool
Feb-22-17 08:04AM  Esperion Therapeutics reports 4Q loss -7.74%
07:47AM  ESPERION THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
07:30AM  Esperion Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Feb-15-17 04:30PM  Esperion to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference GlobeNewswire
Feb-13-17 04:07PM  Esperion Positioned to Capitalize on Phase III Trials
Feb-09-17 12:37PM  Harry Boxers stocks to watch: biotechnology and technology at MarketWatch
Feb-08-17 01:49PM  Four Biotech Stocks Breaking Out at Forbes
Feb-07-17 12:50PM  Whats Next For Esperion Therapeutics Inc (ESPR)? at Insider Monkey +14.04%
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OMENN GILBERT SDirectorMar 21Buy42.261,00042,2601,000Mar 22 08:02 AM
JANNEY DANIELDirectorMar 21Sale45.80350,00016,029,2631,359,967Mar 23 04:45 PM
GOLDSTEIN DOV A MDDirectorMar 21Sale43.48487,35821,190,3261,149,767Mar 23 04:37 PM
Lalwani Narendra D.Chief Operating OfficerNov 01Buy9.935,00049,6505,000Nov 03 05:58 PM